Headwaters Capital Management, an investment management company, released its fourth-quarter 2024 investor letter. A copy of ...

TransMedics is facing allegations of fraud, organ trafficking, and unethical practices that have triggered shareholder ...

TransMedics' stock remains under pressure after a weak third quarter, reduced Q4 guidance, the exit of the company's CFO, and ...

Shares of TransMedics Group (NASDAQ: TMDX) were tanking 14.3% lower as of 10:46 a.m. ET on Friday. The big sell-off came ...

LOS ANGELES, CA / ACCESS Newswire / January 16, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is ...

The law firm of Kirby McInerney LLP is investigating potential claims against TransMedics Group, Inc. (“TransMedics” or the“Company”) (NASDAQ:TMDX). The investigation concerns whether TransMedics ...

JP Morgan has recently reduced TransMedics Group Inc (TMDX) stock to Neutral rating, as announced on December 17, 2024, according to Finviz. Earlier, on November 22, 2024, Needham had reduced the ...

TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today ...

NEW YORK CITY, NY / ACCESSWIRE / January 15, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on ...

TransMedics Gr TMDX has outperformed the market over the past 5 years by 12.34% on an annualized basis producing an average ...

TransMedics is a commercial-stage medical technology company working on organ transplant therapy. Check out more about the ...

Shares of Transmedics (NASDAQ: TMDX) fell 28.1% in December, according to data from S&P Global Market Intelligence. On Dec. 2 ...